Assignee
NYMOX CORP
BS·26 granted patents·6 pending applications·277 citations·filing 1997–2024
Top patents by PatentIndex Score
32 records- 0195US6942858B1Compositions containing bacteriophages and methods of using bacteriophages to treat infectionsNYMOX CORP·Filed 2000·Granted Sep 13, 2005·50 cites·12 claims
- 0294US9243035B2Peptides effective in the treatment of conditions requiring the removal or destruction of cellsNYMOX CORP·Filed 2013·Granted Jan 26, 2016·21 cites·13 claims
- 0392US8569446B2Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cellsNYMOX CORP·Filed 2012·Granted Oct 29, 2013·14 cites·6 claims
- 0488US6924266B2NTP-peptides and method for removal of tumorsNYMOX CORP·Filed 2002·Granted Aug 2, 2005·29 cites·7 claims
- 0587US7514407B2Spheron component peptides and pharmaceutical compositionsNYMOX CORP·Filed 2003·Granted Apr 7, 2009·27 cites·12 claims
- 0687US7270818B2Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis or growth of DMSNYMOX CORP·Filed 2002·Granted Sep 18, 2007·21 cites·1 claims
- 0787US7192929B2Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cellsNYMOX CORP·Filed 2002·Granted Mar 20, 2007·22 cites·5 claims
- 0882US10183058B2Method of preventing or reducing the progression of prostate cancerNYMOX CORP·Filed 2016·Granted Jan 22, 2019·2 cites·14 claims
- 0981US6600947B2Method of detecting amyloid-containing lesions by autofluorescenceNYMOX CORP·Filed 2001·Granted Jul 29, 2003·30 cites·47 claims
- 1080US2025049882A1Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating lutsNYMOX CORP·Filed 2024·Application pending·0 cites
- 1179US6472421B1Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitorNYMOX CORP·Filed 1998·Granted Oct 29, 2002·53 cites·22 claims
- 1275US12090191B2Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTSNYMOX CORP·Filed 2021·Granted Sep 17, 2024·0 cites·14 claims
- 1373US12329802B2Focal treatment of prostate cancerNYMOX CORP·Filed 2022·Granted Jun 17, 2025·0 cites·11 claims
- 1466US11298400B2Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTSNYMOX CORP·Filed 2019·Granted Apr 12, 2022·0 cites·19 claims
- 1564US2024252516A1Combination bph therapy with fexapotide triflutate, a 5-ari, and an alpha blockerNYMOX CORP·Filed 2023·Application pending·0 cites
- 1663US11231421B2Methods of treating multifocal cancerNYMOX CORP·Filed 2019·Granted Jan 25, 2022·0 cites·11 claims
- 1760US11331374B2Focal treatment of prostate cancerNYMOX CORP·Filed 2019·Granted May 17, 2022·0 cites·9 claims
- 1860US10335453B2Compositions and methods for improving sexual functionNYMOX CORP·Filed 2017·Granted Jul 2, 2019·0 cites·14 claims
- 1958US6518314B1Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptionsNYMOX CORP·Filed 2000·Granted Feb 11, 2003·1 cites·9 claims
- 2054US11278588B2Method of treating lower urinary tract symptoms with fexapotide triflutateNYMOX CORP·Filed 2019·Granted Mar 22, 2022·0 cites·16 claims
- 2154US2005260171A1Compositions containing bacteriophages and method of using bacteriophages to treat infectionsNYMOX CORP·Filed 2005·Application pending·0 cites
- 2253US2020360466A1Method of improving lower urinary tract symptomsNYMOX CORP·Filed 2019·Application pending·0 cites
- 2351US10835538B2Method of treating benign prostatic hyperlasia with antibioticsNYMOX CORP·Filed 2018·Granted Nov 17, 2020·0 cites·15 claims
- 2451US7544771B2Protein and its use in diagnosing Alzheimer's diseaseNYMOX CORP·Filed 2005·Granted Jun 9, 2009·0 cites·7 claims
- 2551US6130221APharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptionsNYMOX CORP·Filed 1997·Granted Oct 10, 2000·4 cites·9 claims
- 2649US7572450B2Composition for preventing cell death and/or tissue necrosis resulting from contact with neural thread proteinsNYMOX CORP·Filed 2002·Granted Aug 11, 2009·0 cites·2 claims
- 2746US11628202B2Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasiaNYMOX CORP·Filed 2015·Granted Apr 18, 2023·0 cites·6 claims
- 2846US10172910B2Method of preventing or reducing the incidence of acute urinary retentionNYMOX CORP·Filed 2016·Granted Jan 8, 2019·0 cites·11 claims
- 2945US2020061150A1Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual functionNYMOX CORP·Filed 2018·Application pending·0 cites
- 3042US6413940B1Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMSNYMOX CORP·Filed 1998·Granted Jul 2, 2002·3 cites·1 claims
- 3141US10532081B2Method of ameliorating or preventing the worsening or the progression of symptoms of BPHNYMOX CORP·Filed 2016·Granted Jan 14, 2020·0 cites·18 claims
- 3236US2016361380A1Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferationsNYMOX CORP·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when NYMOX CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →